Iwata T ,et al., Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1. J Thorac Oncol. 2017 Dec;12(12):e205-e207.
Iwata T ,et al., Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1. J Thorac Oncol. 2017 Dec;12(12):e205-e207. 发布于 2018-01-05 11:55 免疫治疗 肿瘤 肺腺癌 赞同6519 条评论 ...
存在自身抗体的患者使用ICI治疗前,应仔细风险和获益,治疗过程中需要谨慎管理,以改善接受ICI治疗患者的护理。 来源:Endo Y, et al. Marked, lasting disease regression and concomitantly induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis...
PD-L1/CD274 Rabbit mAb (A20344)应用:IHC种属:Human Human lung adenocarcinoma Human intestinal adenocarcinoma (negative control sample) [KO Validated] PD-L1/CD274 Rabbit mAb (A19135) 应用:WB,IHC种属:Human,Mouse,Rat Human placenta PD-L1/CD274 Rabbit pAb (A1645) 应用:WB,IHC,IF种属:Human,Mouse...
参考文献:Hong G, Park HS, Yeo MK, Lee D, Chung C. Dynamic changes in pathology and PD-L1 expression in a patient with metastatic lung adenocarcinoma who received pembrolizumab therapy followed by two salvage surgeries two years later: A case report. Thorac Cancer. 2023 Aug;14(23):2320-232...
3.Lin Y Y, Lin L Y , Hang J F,et al. Programmed Death-Ligand 1 (PD-L1)/Thyroid Transcription Factor-1 Double Immunohistochemical Staining Facilitates Scoring of Tumor PD-L1 Expression in Cytopathology Specimens From Lung Adenocarcinoma Patients[J]. Cancer: A Journal of the American Cancer So...
Introduction: Lung adenocarcinoma (LUAD) is a prevalent form of lung cancer originating from lung glandular cells with low survival rates despite recent therapeutic advances due to its diverse and complex nature. Recent evidence suggests a link between ferroptosis and the effectivenes...
免疫组织化学(immunohistochemistry,IHC,简称免疫组化)检测是评估肿瘤组织PD-L1表达状态的一种有效且最常用方法,广泛应用于包括非小细胞肺癌(non-small cell lung cancer, NSCLC)等在内的多种恶性肿瘤中,以识别或辅助预测可能从免疫治疗中获...
21. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint pd-l1 ihc assay comparison project. J Thorac Oncol. 2017;12(2):208-222. 22. Ye M, Huang D, Zhang Q, et al. Heterogeneous programmed death-liga...
of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma[J]．Mol Oncol, 2020, 14(5): 1028-1044.DOI: 10.1002/1878-0261.12664.SunX, LiCW, WangWJ, et al.Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma[J]...